NCT06723756 - A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2025

Conditions

Healthy Participants

Interventions

DRUG

Treatment A: BGF MDI HFO

Participants will receive 2 inhalations of BGF MDI HFO (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 1 Treatment period.

DRUG

Treatment B: BGF MDI HFA

Participants will receive 2 inhalations of BGF MDI HFA (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 2 Treatment periods.

Trial Locations (1)

21225

Research Site, Brooklyn